The majority of patients with epilepsy maintain seizure control during pregnancy. The apparently higher risk of seizures among women treated with oxcarbazepine and the more frequent increases in drug load in the oxcarbazepine and lamotrigine cohorts prompts further studies on relationships with pharmacokinetic changes. Risks associated with status epilepticus appear to be lower than previously reported.
Objective: To explore possible associations between adipose tissue (AT) blood flow (ATBF), AT depot sizes and adipocytederived hormones (adipokines) in women. Subjects: In all, 43 healthy women were divided into four groups: normal-weight (n ¼ 11) and obese (n ¼ 11) pre-menopausal women and normal-weight (n ¼ 10) and obese (n ¼ 11) post-menopausal women. Methods: Fasting levels of adipokines were obtained, and a single-slice computed tomography scan at the level of L4-L5 was used to estimate fat depot sizes. ATBF was assessed by xenon washout while in a fasting state and after oral glucose load. We also measured glucose, insulin and non-esterified fatty acids. Results: Total, subcutaneous and visceral AT areas strongly correlated with ATBF (all Po0.001). Circulating leptin levels strongly and inversely correlated with ATBF (P ¼ 0.001), but this association did not remain after adjustment for body mass index. Adiponectin was not associated with blood flow. Conclusion: ATBF is closely linked to subcutaneous and visceral AT size. Further analyses are needed to determine possible mediators of this association, including mechanistic studies to assess a putative role for leptin as a significant modulator of blood flow.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.